The mechanisms by which peroxisome proliferators are able to regulate metabolic processes such as fat metabolism, while at the same time creating an environment for the development of hepatocellular carcinomas, is a central issue in the non-genotoxic carcinogenesis field. The convergence of two members of the steroid receptor family (peroxisome proliferator-activated receptor, PPAR; and retinold X receptor, RXR) has provided strong support for an oxidative stress component in this cardnogenesis process, but has yet to define clearly a pathway for the classical tumor promotion events associated with peroxisome proliferation. The findings presented here integrate a third member of the steroid receptor family into this process and suggest a novel autocrine loop and mechanism for creating both oxidative stress and tumor promotion. A central regulatory component in this pathway is farnesol which has recently been shown to induce transcription mediated by the steroid receptor family member, farnesoid X receptor (FXR). In this report, it is clearly demonstrated that farnesol can also upregulate the transcriptional events of PPAR, but most likely through a different farnesoid metabolite, resulting in the regulation of an entirely different set of genetic components. Deregulation of the activities of these receptors offers a provocative mechanism for explaining the hepatocarcinogenic effects of peroxisome proliferators in chronically treated rodents.
Introduction
Peroxisomes are subcellular organelles that functionally compartmentalize cellular fi-oxidation reactions. The oxidative enzymes found in peroxisomes are involved in a large variety of metabolic pathways, including: respiration, lipid metabolism, cholesterol metabolism, and gluconeogenesis. Of increasing interest is the large group of compounds that are capable of inducing the proliferation of peroxisomal struc-
•Abbreviations: PPAR, peroxisome proliferator-activated receptor, RXR, retinoid X receptor; FXR, farnesoid X receptor, AOX, acyl-CoA oxidase; AOX-RE, acyl-CoA oxidase response element; EcRE, ecdysone response element; CFA, clofibric acid; JH, juvenile hormone; FPP, farnesylpyrophosphate; F-OH, famesol; HMG-CoA, 3-hydroxy-3-methyglutaryl coenzyme A. tures in rodent livers. This list includes hypolipidemic drugs, environmental pollutants, analgesics, urocosuric drugs, and phthalates (1) . Rodent chemical hepatocarcinogenesis can also be closely correlated with the proliferation of liver peroxisomes, and although a few peroxisome proliferator-inducing agents have been shown to be genotoxic (2, 3) , the majority of compounds show no detectable mutagenic activity (4) , thus falling into the classification of non-genotoxic carcinogens. Over the years, a number of mechanisms have been proposed to explain peroxisome proliferator-induced cancer. Their nongenotoxic nature and the observed ability to stimulate fatty acid P-oxidation enzymes led Reddy and co-workers to propose oxidative stress, in the form of H 2 O 2 buildup and the generation of free radicals, as a possible mechanism for DNA damage and tumor initiation (4) (5) (6) (7) . Although sound in many respects, theories using oxidative stress as a mechanism for tumor initiation leave unexplained the process by which these chemical compounds might also be influencing the checks and balances on cell cycle events and providing an environment for perpetuating the mutations (tumor promotion). Identifying a link between peroxisome proliferator-induced tumor initiation and tumor promotion would be a major advance in defining a mechanism for non-genotoxic carcinogenesis.
The concept of peroxisome proliferation resulting from die stimulation of a variety of oxidative pathways suggests a metabolic disturbance of transcriptional regulation events. From this premise, Reddy and co-workers developed a receptor-based working hypothesis to explain non-genotoxic tumor induction by peroxisome proliferators (4-7). In their original hypothesis, they proposed a ligand-receptor mediated mechanism in which a chemical agent binds with a specific receptor which is then altered to activate a set of genes. This mechanism is strongly supported by the recent discovery of a peroxisome proliferator activated receptor (PPAR*) and its association with members of the retinoid X family (RXR) of receptors. Issemann and Green (8) cloned a mouse peroxisome proliferator-responsive transcription factor (mPPAR) that belongs to the steroid hormone receptor superfamlly of genes. This family of receptors consists of a group of ligand-activated DNA transcription factors diat bind regulatory sequences upstream of their target gene(s) resulting in die activation or repression of specific gene transcription (9,10). Subsequently, it has been shown mat PPAR is a small family of genes with reports of at least a, fi and y isoforms in mouse (11,12), Xenopus (13), rat (14) and human (15, 16 ). An examination of PPAR regulatable promoters suggests mat this receptor family is intimately involved in fat metabolism, including its breakdown (17, 18) , storage (19) and synthesis (20) . The complexity of the PPAR activation pathway has been substantially enhanced by the demonstration that PPAR DNA binding is linked to heterodimerization with a member of the RXR family of receptors (21) , and the recent observations that this regulation is contingent upon associations wim RXR and perhaps odier mammalian cell-specific factors) (22, 23) . Whether PPAR-mediated transcription is a cause or a result of peroxisome proliferation has not been fully established, but these findings circumstantially implicate PPAR-regulated transcriptional events in the propagation of peroxisome proliferation.
Although PPAR transcriptional regulation induced by peroxisome proliferators is well established, the pathway and mechanism for this event is still unresolved. Of critical concern has been the inability to identify an endogenous PPAR ligand from which an established pathway to carcinogenesis might be developed. A variety of in vitro activators of PPAR (8, 24) have been identified but the direct binding of these activators to PPAR has not been established. This complication has lead to the proposal that PPAR activators mediate their activity through some common endogenous factor or ligand. The most recent hypothesized mechanism (25) suggests that peroxisome proliferators interact with fatty acid binding protein complexes creating an increase in intracellular free fatty acids which in turn bind and activate PPAR/RXR complexes. Evidence supporting this hypothesis include: (i) the recent observation that several of these peroxisome proliferators can bind selectively to rat liver fatty acid binding protein (26) , (ii) the observation that a variety of long chain fatty acids can stimulate PPAR-mediated in vitro transcription events (27) , and (iii) the identification of PPAR transcriptional regulatory sequences in the promoter of the rat fatty acid binding protein gene (28) . As provocative as this mechanism sounds, the hydrophobic nature of fatty acids has made it experimentally difficult to establish them as high affinity ligands for PPAR.
Materials and methods

Mammalian cell co-transfection assay
The PPAR transcription assay plasmid constructs were generated as previously described (22) . Briefly, the rat PPARot receptor expression plasmid and pV galactosidase normalization plasmid used in the mammalian co-transfection assay were constructed by directionally cloning the cDNA structure for these genes downstream from the constitutive RSV-LTR promoter in the pRSV eukaryotic expression plasmid (29) . The acyl-CoA oxidase response element (AOX-RE) driven reporter plasmid construction was generated by inserting synthetic oligonucleotides into the polylinker located 5' of the minimal tk promoter in the previously described pBL luciferase vector (30). The integrity of all constructs was verified by DNA sequencing. Transient co-transfection assays were performed as previously described (22) Cell lines, grown as a monolayer in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) fetal calf serum, were plated at 70% confluency 24 h prior to transfection. The recombinant DNA constructs were transiently transfected into CV-1 cells by calcium-phosphate co-precipitation. Medium was removed from transfected cells after 6 h, cells were washed, and experimental drugs were tested in triplicate and at the concentrations described in the figure legends. After 38 h the cells were washed with PBS, lysed with lysis buffer and luciferase activities in cell extracts were assayed using a Dynatech luminometer following the addition of a MgCiyATP/sodium luciferin substrate solution. To determine the efficiency of transfection and to standardize the expression of activity, a pRSV-pVgalactosidase expression plasmid was included in all co-transfections and 30 uJ of each extract was mixed with 200 \i\ of a pVgalactosidase ONPG substrate solution and analyzed for p^-galactosidase activity at 415 nm on an ELISA plate reader (BioRad). Each transfection was performed in triplicate and the average luciferase response for the three independent transfections was normalized to the average pVgalactosidase rate (average luciferase response/Iaverage f)-galactosidase response/min]).
Acyl-CoA oxidase assay
Acyl-CoA oxidase assays were performed essentially as previously described. Briefly, H4IIEC3 cells were grown in Swim's S-77 medium containing 5% fetal calf serum and 20% horse serum. Agents were added to cells for 72 h and cells were scraped from plates, sonicated and the sonicates analyzed for protein content (31) and acyl CoA oxidase activity (32) . 850 J-iJ Of sonicate was incubated at 37°C for 20 min in a 1 ml volume containing; 35 |lM palmitoyl CoA, 50 |il FAD, 1 nM scopoletin, 3 U peroxidase, 0.6 mg BSA, 60 mM Tris-HCl pH 8.3. The reactions were terminated by adding 4 ml 0.1 M sodium borate and fluorescence was read at an excitation wavelength of 395 nm and an emission wavelength of 470 nm. Enzyme activity was expressed as nmol
Yeast transcription assay
Construction of the FXR yeast expression plasmid involved subcloning the cDNA for the FXR gene (33) into the Nco I-Sac I sites downstream of the CUP1 promoter of the yeast expression plasmid YEpE2 (34) . This vector expresses a ubiquitin fusion protein which is subsequently cleaved by endogenous yeast ubiquitinase. The construction of the yeast EcRE f}-galactosidase reporter vector involved fill in blunt ending of a Hind III/ Bam HI fragment (containing the EcRE response element domain), derived from a previously described pBL-EcRE-Luc vector, and subsequent subcloning of this fragment into the blunt ended Xho I site on the YRpC2 yeast reporter vector (35) . The construction of rPPARoc and RXRa yeast expression constructs the yeast YRpC2-AOX-RE reporter vector were as previously described (2236). Receptor and reporter constructs were transformed by the lithium acetate method (37) , into BJ54O9 yeast (MATa, leuTD, /iu3D2OO, ura3-52, trp], gal). The integrity of constructions was verified by DNA sequencing. Yeast transcription assays were performed essentially as previously described (22, 36) . Briefly, prototrophic yeast transformants were grown under selection to an A600 of 0.5-1.0, cells were plated (100 ul) into % well plates, ligand was added (+ 10 mM CuSO 4 ), and plates were incubated at 30°C. After 22 h, A600 nm readings were taken, the cells were lysed, ONPG substrate was added, the plates were incubated at 37°C for 30 min, stop buffer was added, and the plates were read at A415 nm. Normalized pVgalactosidase values were determined from triplicate samples as a measure of (A415/A600) transformant cells-(A415/A6OO) BJ5409 cells.
Results
A cholesterol intermediate as an activator of PPAR
The regulation of peroxisomal fatty acid catabolism pathways by PPARa-mediated transcriptional activities has been well established (17, 18) . More recently it has been demonstrated that the PPARy isoform may be intimately involved with adipocyte-specific lipid storage (19) . The first suggestions of PPAR involvement in fatty acid synthesis are implied in the identification of PPAR responsive promoters in the rat peroxisomal-specific thiolase gene and the rat mitochondrial HMG-CoA synthetase gene (20, 21) . These two enzymes catalyze the condensation of three molecules of acetyl CoA into the six carbon 3-hydroxy-3-methyglutaryl coenzyme A (HMGCoA) molecule, a precursor in the synthesis of cholesterol. Interestingly, the initial step in cholesterol synthesis is mediated by the same enzyme (thiolase) responsible for the final step in peroxisome-specific fatty acid breakdown. As it turns out, a further examination of the literature reveals that many of the intermediates involved in cholesterol synthesis have been identified in peroxisomes (38) . Cholesterol is an essential component of membrane structure and function and is the precursor to a variety of steroid based regulators of metabolic function. To explore the possibility that PPAR may be mediating cholesterol synthesis events, specific inhibitors of the cholesterol synthesis pathway were analyzed for their ability to stimulate or inhibit peroxisome proliferator-induced PPAR transcription ( Figure 1A) . Using an in vitro co-transfection assay containing a rPPARa expression construct and an acylCoA oxidase response element-driven reporter vector (AOX-RE), it was observed that peroxisome proliferator-induced PPAR activity could be repressed by the HMG-CoA reductase inhibitor lovastatin, and that this repression could be overcome by the addition of mevalonate. Furthermore, the squalene synthetase inhibitor, squalestatin 1, had no detectable effect on peroxisome proliferator-induced PPAR activity. These data implicate the presence of a PPAR activating intermediate in the farnesylpyrophosphate (FPP) synthesis pathway.
The 15 carbon FPP structure, a major branch point in the cholesterol synthesis pathway, is produced by the condensa- In a similar assay, famesol was analyzed for its stereospecific activation of PPAR-mediated transcription. rPPARa and Pgalactosidase expression plasmids, and an AOX-RE driven luciferase reporter plasmid were transfected into CV-1 cells and the naturally occurring t,t-farnesol (t,t-F-OH) and a plant derived c.c-famesol (c,c-F-OH) stereoisomer were assay for stimulation of PPAR-mediated transcription. Activity is expressed as the average of triplicate luciferase responses normalized to their respective (J-galactosidase rate.
tion of three mevalonate-derived isoprene pyrophosphate moieties. When in excess, FPP is rapidly converted to famesol and potentially further into farnesoic acid and farnesoic dicarboxylic acids (39) . Physiological roles for free allylic isoprenols is supported in recent reports demonstrating the use of free famesol and geranylgeraniol in isoprenoid biosynthesis and protein isoprenylation (40,41) and studies implicating famesol in the regulated proteolysis of HMG-CoA reductase (42, 43) . To evaluate the possible role of famesol in PPAR activation, naturally occurring trans,trans-fameso\ (t,t-F-OH) and a plant derived stereoisomer cis,cis-fameso] (c,c-F-OH) were examined for their ability to stimulate PPAR transcriptional activity ( Figure 1B) . Only the t,t-isomer of famesol was observed to activate PPAR-mediated transcription. These data strongly implicate famesol or its metabolites in the endogenous regulatory pathway for PPARa. .s.
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Fig. 2. Famesol as an activator of acyl CoA oxidase activity and famesoic acid as a stimulator of PPAR-mediated transcription. (A) t,t-Farnesol was
analyzed for its ability to stimulate acyl CoA oxidase activity in the rat hepatoma cell line H4IIEC3. H4IIEC3 cells were grown in Swim's S-77 medium containing 5% fetal calf serum and 20* horse serum. Cells were exposed to agents for 72 h prior to analysis. Acyl CoA oxidase assays were performed by the fluorometric method of Walusimbi-Kisitu and Harrison (47) . Enzyme activity data were normalized to protein concentration and expressed as a percent of the normalized activity observed with 1 mM CFA. (B) Famesoic acid (FA) was directly evaluated for its effect on PPARmediated transcription. rPPARa and p^galactosidase expression plasmids, and an AOX-RE driven luciferase reporter plasmid were transfected into CV-1 cells and assayed for t,t-farnesoic acid stimulation of PPAR activity as described in Fig. 1 . Activity is expressed as the average of triplicate luciferase responses normalized to their respective pVgalactosidase rate.
PPAR activation appears to be mediated by a metabolite of famesol
In mammalian cells, free famesol may be derived from exogenous sources, or alternatively, formed by the dephosphorylation of FPP (44) and possibly during the turnover of isoprenylated proteins. Recent observations with rodents fed large amounts of famesol or a squalene synthase inhibitor (39, 45) support the hypothesis that excess famesol can be converted into famesoic acid and famesoic dicarboxylic acids. Under the supposition that fatty acids are endogenous regulators of PPAR-induced fatty acid catabolism, t,t-F-OH was evaluated for its effects on acyl-CoA oxidase (AOX) enzyme activity ( Figure 2A) . The incubation of a rat hepatoma cell line (H4IIEC3) with 0.1 mM t,t-F-OH was observed to significantly upregulate the specific activity of endogenous AOX. To further evaluate these observations, the ability of famesoic acid to stimulate PPAR-mediated in vitro transcription was analyzed ( Figure 2B ). Famesoic acid was observed to be more than twice as active as famesol and 10-fold more potent than 
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clofibric acid. The results of these studies strongly suggest famesol stimulated PPAR activity is mediated through its lipophilic properties.
Convergence of PPAR and FXR pathways
These data suggest that PPAR is regulated by famesol or a metabolite of farnesyl pyrophosphate, a precursor of cholesterol and a common intermediate in other branches of isoprenoid metabolism. This activation pathway interestingly converges with the pathway of another steroid receptor family member FXR, a recently described orphan member of the steroid receptor superfamily (33) . Like PPAR, FXR-mediated transcription can be upregulated by famesol. A close comparison of in vitro transcriptional parameters for these two receptors in mammalian and yeast-based assays reveals common and unique characteristics that define their functional activities . Hypothetical mechanism for rodent peroxisome proliferator-induced hepatocarcinogenesis. Direct or indirect peroxisome proliferator stimulation of PPAR results in a dramatic increase in pVoxidation of fatty acids and the production of acetyl CoA. Excess acetyl CoA or acetoacetyl CoA drives the formation of famesylpyrophosphate (FPP) which, when in excess, is converted to farnesol. Farnesol, or perhaps even FPP, is viewed to have multiple fates; one being its conversion to famesoic acid and the other to a juvenile hormone-like mediator of FXR. Famesoic acid acts to upregulate PPAR activity and in an autocatalytic fashion may also serve as source of acetyl CoA through PPAR regulated fatty acid a-oxidation, pVoxidation and/or co-hydroxylation pathways. These maximally induced fatty acid oxidation pathways generate an oxidative stress environment and subsequent DNA damage (tumor initiation). Excess famesol or FPP is also hypothesized to metabolize into a yet to be determined 'X' ligand for FXR, and upregulation of FXR is hypothesized to be linked to cell cycle deregulation events (tumor promotion).
Convergence of three steroid receptor pathways ( Figure 3) . As demonstrated here and in other work (22, 33) , both receptors can be activated by farnesol in a mammalian cell in vitro transcription assay ( Figure 3A) and, similar to previous findings with PPAR (22) , FXR demonstrates an RXRdependent and ligand-independent transcriptional regulation mechanism in yeast based assays ( Figure 3B ). Furthermore, it can be seen that mammalian cell transcription of FXR and PPAR ( Figure 3A ) is contingent upon unique response element motifs that are not interchangeable in this assay. These data suggest that PPAR and FXR mediate different transcriptional events through a common activator or precursor.
Discussion
In the study described here, evidence is presented for the convergence of PPAR, FXR and RXR on a common activator, farnesol. Furthermore, although both receptors are activated by farnesol, they appear to utilize different endogenous farnesol metabolites as ligands and regulate the transcription of different sets of genes. This statement is supported by the observations that: (i) classical peroxisome proliferators could not activate FXR transcription; (ii) the FXR activating compound, juvenile hormone, did not significantly activate PPAR transcription; (iii) the AOX derived PPAR response element could not mediate FXR transcription, and; (iv) the ecdysone response element used with FXR could not mediate PPAR transcription. These data would suggest farnesol serves as a common intermediate for distinct endogenous activators of both PPAR and FXR. A potential scenario for the generation of an endogenous ligand for PPAR is the conversion of farnesol to the fatty acid farnesoic acid, or to one of the farnesol derived dicarboxylic acid forms. These compounds have recently been identified in the urine of rodents fed large amounts of farnesol or a squalene synthase inhibitor (39, 45) , and this conversion pathway is further supported by the acyl CoA oxidase and famesoic acid data presented here. (Figure 2 ). FXR on the other hand, might also be activated by some metabolic product of farnesol or, alternatively, may be activated by a product of the FPP pathway. Interestingly, juvenile hormone, a sesquiterpene derivative of FPP and regulator of insect morphogenesis, selectively activates transcription of FXR. Therefore, the data presented here argue effectively that the stimulation of PPAR mediated fatty acid catabolism is ultimately going to provide the substrate (acetyl CoA) for upregulating farnesol production and consequently the activities of FXR. In addition, these findings suggest that to understand the consequences of peroxisome proliferator activation of PPAR it might ultimately be necessary to understand the consequences of FXR activation. From the above data, a novel working hypothesis to explain peroxisome proliferator-induced tumorigenesis can be generated (Figure 4 ). This hypothesis invokes an indirect involvement of PPAR in tumor promotion. PPAR activation of oxidative catabolism of fatty acids is proposed to generate excess acetyl CoA, driving the overproduction of FPP, which subsequently feeds into the activation pathways of both PPAR and FXR. The autocrine loop of PPAR stimulated farnesol production feeding back to restimulate PPAR is viewed as the vehicle by which oxidative stress, DNA mutations and tumor initiation are created. In the more speculative aspect of the hypothesis, PPAR-linked farnesol production is thought to modulate FXR pathways theorized to be associated with cell cycle or differentiation functions of the cell, thus providing the deregulatory phenomena associated with tumor promotion. This hypothesis does not eliminate the role of oxidative stress in tumorigenesis but rather creates a mechanism wherein the effects of oxidative stress are uncontrolled and/or are immortalized. The link between the two receptor-mediated pathways cannot be ignored. FXR expression in rodents appears to be limited predominately to liver and kidney (33), a distribution pattern somewhat reflective of PPARa (46) . Furthermore, FXR is specifically activated by a classical regulator of insect differentiation and development. The mammalian developmental equivalence to metamorphosis is observed in the events of tissue remodeling and functional reorganization which occur during the morphogenic periods of fetal and perinatal life. Therefore, it can be speculated that the function of juvenile hormone has some ancestral relationship to a mammalian isoprenoid-related transcriptional signaling pathway. Finally, the available limited data suggests that humans are refractory to peroxisome proliferation and the hepatocarcinogenic effects of peroxisome proliferators (47) . A key to the mechanism described above is the linkage of fatty acid breakdown and cholesterol synthesis. This linkage is mediated by the duality of thiolase activity. A comparison of human and rat thiolase genes reveals the presence of two genes in rats displaying differential sensitivities to peroxisome proliferators (48) (49) (50) , while in humans only one gene has been identified (51) . Although it remains to be seen whether or not the human thiolase promoter binds and/or is sensitive to peroxisome proliferators, this deficiency would logically explain the insensitivity of humans to peroxisome proliferatorinduced hepatocarcinogenesis.
In summary, the data presented here provide a novel hypothesis to explain peroxisome proliferator-induced rodent nongenotoxic hepatocarcinogenesis. The role of RXR in the above hypothesis has not been addressed other than its function as a common heterodimer partner. RXR has been proposed to converge at the DNA binding or heterodimerization level with a variety of steroid receptor family members. Its cellular concentration as well as its subtype expression could play a significant role in determining the ultimate activity of PPAR and FXR in the proposed mechanism. Beyond the convergence of receptors at the DNA and protein levels the studies presented here extend this complex network of regulation to include endogenous ligands or ligand precursors, with the caveat that perturbation of one receptor-mediated event can have important consequences on seemingly unrelated metabolic pathways. Validation of this hypothesis will require a thorough dissection of PPAR, FXR and RXR-mediated transcriptional regulation.
